Phase 2 N=50 Ranolazine Among Unrevascularized Chronic Stable Angina Patients
Angina
Primary: Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks — 48; 50; 40; 60 units on a scale — p=>0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=402 Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
Stable Angina · Coronary Disease
Primary: Number of Myocardial Ischemia Attacks in 24 Hours — 2.3; 3.8 ischemic attacks per 24 hours — p=<0.0001
Phase 2 N=186 Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
Chronic Stable Angina
Primary: Change in Total Exercise Time (Seconds) — 24.3; 18.2; 33.9; 11.9 second
Phase 3 N=2,651 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease · Angina Pectoris
Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…
Phase 2 N=79 Phase II Study of STA-2 in Patients With Chronic Stable Angina
Chronic Stable Angina
Primary: Change in Total Exercise Time — 450.39; 411.15 seconds — p=0.025
Phase 4 N=171 An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
Chronic Angina
Primary: Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and…
Phase 2 N=547 Safety Study of Apixaban in Recent Acute Coronary Syndrome
Acute Coronary Syndrome (ACS)
Primary: Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or…
Phase 1 N=64 A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
Angina Pectoris · Coronary Heart Disease · Calcitonin Gene-related Peptide Receptor
Primary: Number of Participants With Clinical Adverse Events (AEs) — 7; 1; 5 Participants
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Phase 3 N=9,326 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
Acute Coronary Syndrome
Primary: Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke — 10.06; 24.64; 10.96; 24.13 percentage of…
Phase 4 N=31 Ranolazine and Microvascular Angina by PET in the Emergency Department
Microvascular Angina
Primary: Coronary Flow Reserve — 1.6; 1.6; 1.9; 1.6 ratio
Phase 4 N=949 Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Angina Pectoris · Coronary Artery Disease · Type 2 Diabetes Mellitus
Primary: Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment — 5.2; 4.5 angina attacks per week — p=0.008
N/A N=90 Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI)
Myocardial Infarction
Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05
N/A N=142 Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia
Microvascular Coronary Dysfunction (MCD)
Primary: Seattle Angina Questionnaire (SAQ) — 68.09; 66.7; 58.4; 51.17 Units on scale
N/A N=34 Comparative Effectiveness of Decision Aids for Stable Chest Discomfort
Coronary Artery Disease · Stable Angina
Primary: Total Knowledge Score — 2.83; 4.0 knowledge score
Phase 4 N=28 Ranolazine in Ischemic Cardiomyopathy
Cardiomyopathy · Chest Pain · Dyspnea
Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Phase 4 N=64 Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
Stable Angina Pectoris · Atherosclerosis
Primary: Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12). — 330.60; 164.08 Relative change versus baseline (%)
Phase 4 N=12 Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
Microvascular Angina
Primary: Seattle Angina Questionnaire Score — 83.3; 29.2; 74.1; 67.6 units on a scale
Phase 2 N=26 Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
Microvascular Angina
Primary: Change in Seattle Angina Questionnaire Score Regarding Angina Frequency — 0.70; 0.27 score on a scale
N/A N=21 PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
Coronary Artery Disease
Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries
Phase 4 N=30 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
Coronary Artery Disease
Primary: Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo — 8.8; 10.7 mL/min — p=0.756
Phase 3 N=112 Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
Chronic Myocardial Ischemia · Refractory Angina Pectoris · Advanced Coronary Heart Disease
Primary: Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) Using the Modified Bruce Protocol — 108.7; 90.0 seconds
Phase 4 N=7,119 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
Cardiovascular Disease · Interventional Cardiology
Primary: Number of Participants With BARC Type 2, 3, or 5 — 141; 250 Participants
Phase 2 N=53 Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study
Critical Limb Ischemia
Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…
N/A N=200 Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
Stable Angina
Primary: Exercise Time on Treadmill — 28.4; 11.8 seconds
Phase 4 N=54 Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Slow Coronary Flow · Normal, or Near Normal Coronary Angiography · Stable Angina
Primary: Angina Episode Frequnecy — 2.28; 1.68 episodes per week
Phase 2 N=95 PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
Heart Failure · Myocardial Ischemia · Angina Pectoris
Primary: Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B) — 0; 0; 1 Participants
N/A N=626 Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI
Post Procedural Myocardial Infarction
Primary: Peri-Procedural Myocardial Injury — 23; 29 Participants
Phase 3 N=2,198 European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
Acute Coronary Syndrome
Primary: The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding — 5.1; 8.5 percentage of participants — p=0.0014